Non-exclusive discount agreement for medicines containing budesonide and formoterol

Summary

The tender concerns non-exclusive discount agreements for medicines containing the active ingredients budesonide and formoterol, excluding IHP products in the strength 80 µg/4.5 µg (ATC R03AK07). Interested pharmaceutical companies must identify the medicines covered by their offer in the contract annex. The agreement is planned to run from 1 October 2026 to 30 September 2028, with one possible 12-month extension, and will end automatically when an exclusive agreement for the same active ingredient enters into force.